Pharming Group (NASDAQ:PHAR) Stock Price Up 4.3% – Still a Buy?

Pharming Group (NASDAQ:PHAR) shares traded up 4.3% during mid-day trading on Wednesday . The company traded as high as $9.56 and last traded at $9.32. 651 shares were traded during trading, a decline of 86% from the average session volume of 4,803 shares. The stock had previously closed at $8.94.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and issued a $37.00 price target on shares of Pharming Group in a report on Thursday.

Pharming Group Price Performance

The stock has a market capitalization of $562.99 million, a PE ratio of -43.68 and a beta of 0.15. The company has a current ratio of 3.39, a quick ratio of 2.65 and a debt-to-equity ratio of 0.40. The business has a fifty day moving average price of $8.03 and a 200-day moving average price of $8.56.

Pharming Group (NASDAQ:PHAR) last posted its quarterly earnings results on Thursday, August 1st. The company reported ($0.01) EPS for the quarter. Pharming Group had a negative return on equity of 5.69% and a negative net margin of 4.65%. The business had revenue of $74.09 million for the quarter, compared to analysts’ expectations of $71.95 million. During the same period last year, the business posted $0.02 earnings per share. Research analysts expect that Pharming Group will post -0.15 EPS for the current fiscal year.

Institutional Investors Weigh In On Pharming Group

An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC boosted its holdings in shares of Pharming Group (NASDAQ:PHAR) by 32.3% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 23,435 shares of the company’s stock after purchasing an additional 5,725 shares during the period. Silverberg Bernstein Capital Management LLC’s holdings in Pharming Group were worth $196,000 at the end of the most recent reporting period. 0.03% of the stock is owned by institutional investors and hedge funds.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.